New drug trial offers hope for Tough-to-Treat lymphoma
NCT ID NCT07180771
Summary
This study is testing an experimental drug called BR101801 for people with peripheral T-cell lymphoma that has returned or hasn't responded to standard treatments. The trial will enroll 44 participants to see how well the drug shrinks tumors and how safe it is. Patients will take the drug once daily and researchers will track their response and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.